27 May 2020
(“genedrive” or the “Company”)
Result of General Meeting
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that at the General Meeting held earlier today, the Resolutions proposed were duly passed by shareholders.
The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 7 May 2020 which is available on the Company’s website www.genedriveplc.com.
It is expected that Admission of the Placing Shares and the Broker Option Shares will become effective at 8.00 a.m. on 28 May 2020. Following Admission, the Company will have 44,870,071 Ordinary Shares of 1.5p in issue each with equal voting rights. No shares are held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA’s Disclosure Guidance and Transparency Rules.
Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the Proposed Placing and Broker Option announcement issued on 5 May 2020.
+44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser, Joint Bookrunner and Joint Broker)
+44 (0)20 7418 8900
James Steel / Oliver Jackson / Jock Maxwell Macdonald
finnCap (Joint Bookrunner and Joint Broker)
+44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)
+44 (0)20 7933 8780 or email@example.com
Paul McManus / Anna Dunphy
+44 (0)7980 541 893 / +44 (0)7876 741 001
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The company recently announced the development of the high throughput SARS-CoV-2 assay, based on Genedrive PCR chemistry.